ERBB2 and non-small cell lung carcinoma: Before T-DXd approval, advanced HER2-mutant NSCLC was often treated using protocols similar to those for driver gene-negative cases, relying primarily on standard chemotherapy with/without immunotherapy or anti-angiogenic drugs due to the absence of targeted therapies specific to HER2 mutations (Tsuboi et al., 2023; Wu et al., 2024).